

ARNOLD & PORTER LLP

202.942.5000
202.942.5999 Fax
555 Twelfth Street, NW
Washington, DC 20004-1206



February 19, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Application No. 10/643,681
Filed: August 18, 2003
Title: **Methods for Regulating Gastrointestinal Motility**
Applicants: Orville G. KOLTERMAN *et al.*
Atty. Docket: 18528.642 / 254/057CON

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

1. an Information Disclosure Statement;
2. a PTO-1449 Form (11 pages); and
3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.


In the event that extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees under 37 C.F.R. §§ 1.16 or 1.17 are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter Deposit Account No. 50-2387, referencing matter number 18528.642. A duplicate copy of this letter is enclosed.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "David R. Marsh".

David R. Marsh (Reg. No. 41,408)
Milan M. Vinnola (Reg. No. 45,979)

Attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Orville G. KOLTERMAN *et al.*

Application No. 10/643,681

Filed: August 18, 2003

For: ***Methods for Regulating
Gastrointestinal Motility***

Group Art Unit: 1646

Examiner: To Be Assigned

Atty. Docket: 18528.642 / 254/057CON

Confirmation No.: 4614

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the references listed on the attached Form PTO-1449. These references were previously considered in earlier filed U.S. Patent Application Serial No. 09/572,062, filed May 22, 2000, which issued as U.S. Patent No. 6,608,029, which is a continuation of U.S. Patent Application Serial No. 08/302,069, filed September 7, 1994, which issued as U.S. Patent No. 6,114,304, which is a continuation-in-part of U.S. Application Serial No. 08/118,381, filed September 7, 1993, now abandoned, upon which the instant application relies on for an earlier effective filing date under 35 U.S.C. 120. Applicants further submit that the references filed in the Information Disclosure Statement in the earlier applications complied with 37 C.F.R. 1.98(a)-(c). Accordingly, Applicants submit that under 37 C.F.R. 1.98(d)(1)-(2), copies of the listed references need not be provided. However, the Examiner is requested to notify the Applicants should he/she require a copy of any or all of the listed references.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Because this Information Disclosure Statement is being submitted prior to issuance of the first action on the merits of the above-captioned application, no certification or fee is required.

Respectfully submitted,


A handwritten signature in black ink, appearing to read "D. R. Marsh".

David R. Marsh (Reg. No. 41,408)

Milan M. Vinnola (Reg. No. 45,979)

Date: February 19, 2004

ARNOLD & PORTER
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile



INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1	5,124,314	6/1992	Cooper			
	AB1	5,166,192	11/1992	Mathias			
	AC1	5,175,145	12/1992	Cooper			
	AD1	5,187,154	2/1993	Phillips <i>et al.</i>			
	AE1	5,234,906	8/1993	Young <i>et al.</i>			
	AF1	5,260,275	11/1993	Cooper <i>et al.</i>			
	AG1	5,264,372	11/1993	Beaumont <i>et al.</i>			
	AH1	5,266,561	11/1993	Cooper <i>et al.</i>			
	AI1	5,281,581	1/1994	Cooper <i>et al.</i>			
	AJ1	5,367,052	11/1994	Cooper <i>et al.</i>			
	AK1	5,376,638	12/1994	Young <i>et al.</i>			
	AL1	5,580,953	12/1996	Albrecht <i>et al.</i>			
	AM1	5,686,411	11/1997	Gaeta <i>et al.</i>			
	AN1	6,114,304	9/2000	Kolterman <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AN1	0 289 287 A2	11/1988	Europe			Yes No
	AO1	93/10146	5/1993	PCT			Yes No
	AP1	93/10147	5/1993	PCT			Yes No
	AQ1	92/20367	11/1992	PCT			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR1

Alam *et al.*, "Selective Antagonism of Calcitonin-induced Osteoclastic Quiescence (Q Effect) by Human Calcitonin Gene-Related Peptide-(Val¹⁸Phe³⁷)", *Biochem. Biophys. Res. Commun.*, 179(1):134-139 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA2

Amara *et al.*, "Expression in Brain of a Messenger RNA Encoding a Novel Neuropeptide Homologous to Calcitonin Gene-Related Peptide", Science, 229:1094-1097 (1985)

AB2

Brain *et al.*, "Amylin Amide, Which is Structurally Similar to Calcitonin Gene-Related Peptide (CGRP), Stimulates Increased Blood Flow In Vivo", Eur. J. Pharmacol., 183:221 (1990)

AC2

Brener *et al.*, "Regulation of the Gastric Emptying of Glucose", Gastroenterology, 85:76-82 (1983)

AD2

Briner *et al.*, "Tageszeitliche Schwankungen der Glukose-toleranz bei Diabetikern und Nichtdiabetiker, unter besonderer Berücksichtigung der Magenentleerung", Schweiz Rundsh Med. Prax., 68:1666-1672 (1979)

AE2

Broderick *et al.*, "Human and Rat Amylin have no Effects on Insulin Secretion in Isolated Rat Pancreatic Islets", Biochem. Biophys. Res. Comm., 177:932-938 (1991)

AF2

Camilleri & Malagelada, "Abnormal Intestinal Motility in Diabetes with the Gastroparesis Syndrome", European Journal of Clinical Investigation, 14:420-427 (1984)

AG2

Campbell *et al.*, "Gastric Emptying in Diabetic Autonomic Neuropathy", Gut, 18:462-467 (1977)

AH2

Cavallo-Perin *et al.*, "Gastric Emptying of Liquids and Solids Evaluated by Acetaminophen Test in Diabetic Patients with and without Autonomic Neuropathy", European Review for Medical & Pharmacological Sciences, XIII:205-209 (1991)

AI2

Chance *et al.*, "Anorexia Following the Intrahypothalamic Administration of Amylin", Brain Research, 539:352-354 (1991)

AJ2

Chantry *et al.*, "Cross-reactivity of Amylin with Calcitonin-Gene-Related Peptide Binding Sites in Rat Liver and Skeletal Muscle Membranes", Biochem. J., 277:139-143 (1991)

AK2

Clouse and Lustman, "Gastrointestinal Symptoms in Diabetic Patients: Lack of Association with Neuropathy", The American Journal of Gastroenterology, 84(8):868-872 (1989)

AL2

Cohen *et al.*, The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

1646

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA3

Cooper *et al.*, "Purification and Characterization of a Peptide from Amyloid-Rich Pancreases of Type 2 Diabetic Patients", Proc. Natl. Acad. Sci. USA, 84:8628-8632 (1987)

AB3

Cooper *et al.*, "Amylin Found in Amyloid Deposits in Human Type 2 Diabetes Mellitus May be a Hormone that Regulates Glycogen Metabolism Skeletal Muscle", Proc. Natl. Acad. Sci. USA, 85:7763-7766 (1988)

AC3

Cooper *et al.*, "The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain", Progress in Growth Factor Research, 1:99-105 (1989)

AD3

Cooper *et al.*, "Amylin and the Amylin Gene: Structure, Function and Relationship to Islet Amyloid and to Diabetes Mellitus", Biochem. Biophysica Acta., 1014:247-258 (1989)

AE3

Cooper *et al.*, "Amylin Action: Physiologic Basis and Pathologic Correlations", Diabetes, 497-500 (1991)

AF3

Cotroneo *et al.*, "Gastric Emptying Rate and Hormonal Response in Type II Diabetics", Diabetes Res., 17:99-104 (1991)

AG3

Daniel *et al.*, "Use of Glucagon in the Treatment of Acute Diverticulitis", Br. Med. J., 3:720 (1974)

AH3

Dao *et al.*, "Lack of Modulation of Gastric Emptying by Acute Hyperglycemia in Type 2 Diabetes Mellitus", Gastroenterology, 98:A342 (1990)

AI3

Deems *et al.*, "Amylin or CGRP (-37) Fragments Reverse Amylin-Induced Inhibition of ¹⁴C-Glycogen Accumulation", Biochem. Biophys. Res. Comm., 181(1):116-120 (1991)

AJ3

Eisenberg *et al.*, "Synchronous Gastric Motor and Secretory Activity in Normal and Diabetic Dogs: The importance of Variation in Blood Sugar Levels", Bulletin de la Societe Internationale de Chirurgie, 3:191-198 (1972)

AK3

Feldman *et al.*, "Abnormal Gastric Function in Longstanding, Insulin-Dependent Diabetic Patients", Gastroenterology, 77:12-17 (1979)

AL3

Feldman *et al.*, "Disorders of Gastrointestinal Motility Associated with Diabetes Mellitus", Ann. Int. Med., 98:378-384 (1983)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA4	Feldman <i>et al.</i> , "Gastric Emptying of Solid Radiopaque Markers: Studies in Healthy Subjects and Diabetic Patients", <u>Gastroenterology</u> , 87:895-902 (1984)	
	AB4	Follett <i>et al.</i> , "Effect of Amylin on Insulin Receptor Kinase Activity <i>In Vivo</i> in the Rat", <u>Clinical Research</u> , 39(1):39A (1991)	
	AC4	Forster and Dockray, "Immunoneutralization suggests that calcitonin gene related peptide regulates gastric emptying in the rat", <u>Neurosci. Lett.</u> , 131:5-7 (1991)	
	AD4	Franken <i>et al.</i> , "The Use of Glucagon in Hydrostatic Reduction of Intussusception: A Double-Blind Study of 30 Patients", <u>Radiology</u> , 146:687 (1983)	
	AE4	Fraser <i>et al.</i> , "Hyperglycaemia slows gastric emptying in Type 1 (insulin-dependent) diabetes mellitus", <u>Diabetologia</u> , 33:675-680 (1990)	
	AF4	Fraser <i>et al.</i> , "Hyperglycaemia Stimulates Pyloric Motility in Normal Subjects", <u>Gut</u> , 32:475-478 (1991)	
	AG4	Fraser <i>et al.</i> , "Effect of Insulin-Induced Hypoglycaemia in Antral, Pyloric and Duodenal Motility in Fasting Subjects", <u>Clin. Sci.</u> , 81:281-285 (1991)	
	AH4	Frontoni <i>et al.</i> , "In Vivo Insulin Resistance Induced by Amylin Primarily Through Inhibition of Insulin-Stimulated Glycogen Synthesis in Skeletal Muscle", <u>Diabetes</u> , 40:568-573 (1991)	
	AI4	Gaber <i>et al.</i> , "Changes in Gastric Emptying in Recipients of Successful Combined Pancreas-Kidney Transplants", <u>Dig. Dis.</u> , 9:437-443 (1991)	
	AJ4	Galeazza <i>et al.</i> , "Islet Amyloid Polypeptide (IAPP) Competes for Two Binding Sites of CGRP", <u>Peptides</u> , 12:585-591 (1991)	
	AK4	Gardiner <i>et al.</i> , "Antagonistic Effect of Human α -Calcitonin Gene-related Peptide (8-37) on regional Hemodynamic Actions of Rat Islet Amyloid Polypeptide in Conscious Long-Evans Rats", <u>Diabetes</u> , 40:948-951 (1991)	
	AL4	Gedulin <i>et al.</i> , "Amylin Secretion from the Perfused Pancreas: Dissociation from Insulin and Abnormal Elevation in Insulin-Resistant Diabetic Rats", <u>Biochem. Biophys. Res. Commun.</u> , 180(2):782-789 (1991)	
EXAMINER			DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.</p>			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA5	Gilbey <i>et al.</i> , "Amylin Lowers Serum Calcium in Pagets Bond Disease Further Evidence for a Role in Calcium Metabolism", <u>J. Bone Mineral Res.</u> , S293 (1991)	
	AB5	Gill <i>et al.</i> , "Effects of Ciglitazone on Endogenous Plasma Islet Amyloid Polypeptide and Insulin Sensitivity in Obese-Diabetic Viable Yellow Mice", <u>Life Sciences</u> , 48:703-710 (1991)	
	AC5	Glauser <i>et al.</i> , "Intravenous Glucagon in the Management of Esophageal Food Obstruction", <u>J. Am. Coll. Emergency Physns.</u> , 8:228 (1979)	
	AD5	Gomez-Foix <i>et al.</i> , "Anti-Insulin Effects of Amylin and Calcitonin-Gen-Related Peptide on Hepatic Glycogenmetabolism", <u>Biochem. J.</u> , 276:607-610 (1991)	
	AE5	<u>Goodman and Gilman's The Pharmacological Basis of Therapeutics</u> , Chapter 38, Pergamon Press, Eighth Edition (1990)	
	AF5	Hartter <i>et al.</i> , "Basal and Stimulated Plasma Levels of Pancreatic Amylin Indicate its Co-Secretion with Insulin in Humans", <u>Diabetologia</u> , 34:52-54 (1991)	
	AG5	Horowitz <i>et al.</i> , "Gastric and Oesophageal Emptying in Patients with Type 2 (Non-Insulin-Dependent) Diabetes Mellitus", <u>Diabetologia</u> , 32:151-159 (1989)	
	AH5	Horowitz <i>et al.</i> , "Disordered Gastric Motor Function in Diabetes Mellitus", <u>Scand. J. Gastroenterol.</u> , 26:673-684 (1991)	
	AI5	Horowitz <i>et al.</i> , "Relationships Between Oesophageal Transit and Solid and Liquid Gastric Emptying in Diabetes Mellitus", <u>Eur. J. Nucl. Med.</u> , 18:229-234 (1991)	
	AJ5	Horowitz <i>et al.</i> , "Relationship Between Oral Glucose Tolerance and Gastric Emptying in Normal Healthy Subjects", <u>Diabetologia</u> , 36:857-862 (1993)	
	AK5	Horowitz <i>et al.</i> , "Disordered Gastric Motor Function in Diabetes Mellitus", <u>Diabetologia</u> , 37:543-551 (1994)	
	AL5	Huang <i>et al.</i> , "Hyperamylinemia, Hyperinsulinemia, and Insulin Resistance in Genetically Obese LA/N- <i>cp</i> Rats", <u>Hypertension</u> , 19:I-101-I-109 (1992)	
EXAMINER			DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.</p>			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA6	"Introduction to Cleavage Techniques", Strategies in Peptides Synthesis, Applied Biosystems, Inc. (1990)	
	AB6	Isal <i>et al.</i> , "Gastric Emptying of Solid Radiopaque Markers in Diabetic Patients", <u>Gastroenterology</u> , 88:1094 (1985)	
	AC6	Janssens <i>et al.</i> , "Improvement of Gastric Emptying in Diabetic Gastroparesis by Erythromycin", <u>N. Engl. J. Med.</u> , 322:1028-1031 (1990)	
	AD6	Jonderko <i>et al.</i> , "Calcitonin Suppresses Gastric Emptying of a Radiolabelled Solid Meal in Humans", <u>Br. J. Clin. Pharmacol.</u> , 24:103-105 (1987)	
	AE6	Jonderko <i>et al.</i> , "Effect of Calcitonin on Gastric Emptying", <u>Digestion</u> , 40:191-196 (1988)	
	AF6	Jonderko, "Effect of Calcitonin on Gastric Emptying in Patients with an Active Duodenal Ulcer", <u>Gut</u> , 30:430-435 (1989)	
	AG6	Kanatsuka <i>et al.</i> , "Secretion of Islet Amyloid Polypeptide in Response to Glucose", <u>FEBS Lett.</u> , 259(1):199-201 (1989)	
	AH6	Katsoulis <i>et al.</i> , "Effects of Calcitonin Gene Related Peptides (CGRP), Calcitonin (CT) and Islet Amyloid Polypeptide (IAPP) on Gastric Motility of Guinea Pig and Rat", <u>Regul. Pept.</u> , 26:77 (1989)	
	AI6	Keshavarzian <i>et al.</i> , "Gastric Emptying in Patients with Insulin-Requiring Diabetes Mellitus", <u>Am. J. Gastroent.</u> , 82:29-35 (1987)	
	AJ6	Koda <i>et al.</i> , "Amylin Concentrations and Glucose Control", <u>The Lancet</u> , 339:1179-1180 (1992)	
	AK6	Kolterman <i>et al.</i> , "Infusion of Amylin Agonist, Reduces Postprandial Hyperglycemia in Subjects with Type I Diabetes (IDDM)", <u>Clinical Research</u> , 42(1):87A (1994)	
	AL6	Kong <i>et al.</i> , "Infusion of Pramlintide, a Human Amylin Analogue, Delays Gastric Emptying in Men with IDDM", <u>Diabetologia</u> , 40:82-88 (1997)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. * Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA7	Koopmans <i>et al.</i> , "Amylin Induced <i>In Vivo</i> Insulin Resistance in Conscious Rats: The Liver is More Sensitive to Amylin than Peripheral Tissues", <u>Diabetologia</u> , 34:218-224 (1991)	
	AB7	Leighton and Cooper, "Pancreatic Amylin and Calcitonin Gene-Related Peptide Cause Resistance to Insulin in Skeletal Muscle <i>In Vitro</i> ", <u>Nature</u> , 335:632-635 (1988)	
	AC7	Lenz, "Calcitonin and CGRP Inhibit Gastrointestinal Transit Via Distinct Neuronal Pathways", <u>Am. J. Physiol. Soc'y</u> , G920-G924 (1988)	
	AD7	Lin <i>et al.</i> , "Gastric Emptying of Solid Meal in Diabetic Patients", <u>Nippon Shokakigyo Gakkai Zasshi</u> , 84:1-5 (1987)	
	AE7	Loo <i>et al.</i> , "Gastric Emptying in Patients with Diabetes Mellitus", <u>Gastroenterology</u> , 86:485-494 (1984)	
	AF7	Lupien and Young, "No Measurable Effect of Amylin on Lipolysis in Either White or Brown Isolated Adipocytes from Rats", <u>Diabetes Nutrition and Metabolism - Clinical and Experimental</u> , 6:13-18 (1993)	
	AG7	MacGregor <i>et al.</i> , "The Effect of Acute Hyperglycemia on Gastric Emptying in Man", <u>Gastroenterology</u> , 70:190-196 (1976)	
	AH7	McCallum <i>et al.</i> , "Definition of a Gastric Emptying Abnormality in Patients with Anorexia Nervosa", <u>Digestive Diseases and Sciences</u> , 30(8):713-722 (1985)	
	AI7	Mecklenbeck <i>et al.</i> , "Gastric Emptying in Diabetic Neuropathy: Two Different Forms of Disturbed Kinetics", <u>Euro. J. Nucl. Med.</u> , 18:FP-3H3-1 (1991)	
	AJ7	Moberg & Carlberger, "Gastric Emptying in Healthy Subjects and in Patients with Various Malabsorptive States", <u>Scand. J. Gastroent.</u> , 9:17-21(1973)	
	AK7	Molina <i>et al.</i> , "Induction of Insulin Resistance <i>In Vivo</i> by Amylin and Calcitonin Gene-Related Peptide", <u>Diabetes</u> , 39:260-265 (1990)	
	AL7	Moore and Rink, "Amylin Activates Adenylyl Cyclase in Rat Soleus Muscle", <u>Diabetes</u> , 42:5, 821 (1993)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. * Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA8	Moore <i>et al.</i> , "Co-Secretion of Amylin and Insulin From Cultured Islet β -Cells: Modulation by Nutrient Secretagogues, Islet Hormones and Hypoglycemic Agents", <u>Biochem. Biophys. Res. Commun.</u> , 179(1):1-9 (1991)	
	AB8	Nagai <i>et al.</i> , "A Case of Diabetic Neuropathy Accompanied by Relapsing Paralytic Ileus Due to Omeprazole Administration", <u>J. Japan. Diab. Soc.</u> , 36(9):733-739 (1993)	
	AC8	Nakanome <i>et al.</i> , <u>Tohoku J. Exp. Med.</u> , 139:205-215 (1983)	
	AD8	Nowak <i>et al.</i> , "Evidence for Accelerated Gastric Emptying in Asymptomatic Patients with Insulin-Dependent Diabetes Mellitus", <u>Gastroenterology</u> , 98:A378 (1990)	
	AE8	Ogawa <i>et al.</i> , "Amylin Secretion from the Rat Pancreas and its Selective Loss after Streptozotocin Treatment", <u>J. Clin. Invest.</u> , 85:973-976 (1990)	
	AF8	Ohsawa <i>et al.</i> , "Islet Amyloid Polypeptide Inhibits Glucose-Stimulated Insulin Secretion from Isolated Rat Pancreatic Islets", <u>Biochem. Biophys. Res. Commun.</u> , 160(2):961-967 (1989)	
	AG8	Pehling <i>et al.</i> , "Abnormal Meal Carbohydrate Disposition in Insulin-Dependent Diabetes", <u>J. Clin. Invest.</u> , 74:985-991 (1984)	
	AH8	Phillips <i>et al.</i> , "Rapid Gastric Emptying in Patients with Early Non-Insulin-Dependent Diabetes Mellitus", <u>N. Eng. J. Med.</u> , 10:130-131 (1991)	
	AI8	Phillips <i>et al.</i> , "Rapid Gastric Emptying of an Oral Glucose Solution in Type 2 Diabetes Mellitus", <u>J. Nucl. Med.</u> , 33:1496-1500 (1992)	
	AJ8	Phillips <i>et al.</i> , "Reduced Postprandial Blood Glucose Levels in Recently Diagnosed Non-Insulin-Dependent Diabetics Secondary to Pharmacologically Induced Delayed Gastric Emptying", <u>Digestive Diseases and Sciences</u> , 38:51-58 (1993)	
	AK8	Plourde <i>et al.</i> , "CGRP 8027 Blocks the Inhibition of Gastric Emptying Induced by Intravenous Injection of α -CGRP in Rats", <u>Life Sciences</u> , 52:857-862 (1993)	
	AL8	Raybould <i>et al.</i> , "Central Nervous System Action of Calcitonin Gene-Related Peptide to Inhibit Gastric Emptying in the Conscious Rat", <u>Peptides</u> , 9:735-739 (1988)	
EXAMINER			DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.</p>			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA9	"Remington's Pharmaceutical Sciences", Alfonso Gennaro, Editor, Mack Publishing Company, 18 th Edition, TABLE OF CONTENTS	
	AB9	Roden <i>et al.</i> , "Effects of Islet Amyloid Polypeptide on Hepatic Insulin Resistance and Glucose Production in the Isolated Perfused Rat Liver", <u>Diabetologia</u> , 35:116-120 (1992)	
	AC9	Saltzman and McCallum, "Diabetes and the Stomach", <u>Yale J. Biol. Med.</u> , 56:179-187 (1983)	
	AD9	Sambrook <i>et al.</i> , "Molecular Cloning -- A Laboratory Manual", Second Edition, Cold Spring Harbor Laboratory Press, TABLE OF CONTENTS (1989)	
	AE9	Sanke <i>et al.</i> , "Plasma Islet Amyloid Polypeptide (Amylin) Levels and Their Responses to Oral Glucose in Type 2 (Non-Insulin-Dependent) Diabetic Patients", <u>Diabetologia</u> , 34:129-132 (1991)	
	AF9	Scarpello <i>et al.</i> , "Gastric Emptying of Solid Meals in Diabetics", <u>British Medical Journal</u> , 2:671-673 (1976)	
	AG9	Schvarcz <i>et al.</i> , "Hypoglycaemia Increases the Gastric Emptying Rate in Patients with Type 1 Diabetes Mellitus", <u>Diabetic Medicine</u> , 10:660-663 (1993)	
	AH9	Scott and Loyd-Mostyn, "Acute Autonomic Dysfunction in Diabetic Ketoacidosis", "The Lancet", 1:590 (1976)	
	AI9	Silvestre <i>et al.</i> , "Inhibitory Effect of Rat Amylin on the Insulin Responses to Glucose and Arginine in the Perfused Rat Pancreas", <u>Regulatory Peptides</u> , 31:23-31 (1990)	
	AJ9	Stacher <i>et al.</i> , "Oesophageal and Gastric Motility Disorders in Patients Categorised as Having Primary Anorexia Nervosa", <u>Gut</u> , 27:1120-1126 (1986)	
	AK9	Stephens <i>et al.</i> , "Presence of Liver CGRP/Amylin Receptors in Only Nonparenchymal Cells and Absence of Direct Regulation of Rat Liver Glucose Metabolism by CGRP/Amylin", <u>Diabetes</u> , 40:395-400 (1991)	
	AL9	Stower <i>et al.</i> , "A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease", <u>Br. J. Surg.</u> , 69:591-592 (1982)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. * Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA10	Torsdottir <i>et al.</i> , "A Small Dose of Soluble Alginate-Fiber Affects Postprandial Glycemia and Gastric Emptying in Humans with Diabetes", <u>J. Nutr.</u> , 121:795-799 (1991)	
	AB10	Wang, "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", <u>Journal of Parenteral Science and Technical</u> , Technical Report No. 10, Supp. 42:2S (1988)	
	AC10	Wang <i>et al.</i> , "Amylin is More Potent and More Effective than Glucagon in Raising Plasma Glucose Concentration in Fasted, Anesthetized Rats", <u>Biochem. Biophys. Res. Commun.</u> , 181(3):1288-1293 (1991)	
	AD10	Wang <i>et al.</i> , " ⁸⁻³⁷ h-CGRP Antagonizes Actions of Amylin on Carbohydrate Metabolism <i>In Vitro</i> and <i>In Vivo</i> ", <u>FEBS Letts.</u> , 291(2):195-198 (1991)	
	AE10	Webb <i>et al.</i> , "Glucagon and Ureteric Calculi", <u>Med. J. Aust.</u> , 144:124 (1986)	
	AF10	Woodward <i>et al.</i> , "Postgastrectomy Syndromes", <u>Surgical Clinics of North America</u> , 67(3):509-520 (1987)	
	AG10	Wright <i>et al.</i> , "Diabetic Gastroparesis: An Abnormality of Gastric Emptying of Solids", <u>Gastroenterology</u> , 84:1355 (1983)	
	AH10	Young <i>et al.</i> , "Effects of Amylin on Glucose Metabolism and Glycogenolysis <i>In Vivo</i> and <i>In Vitro</i> ", <u>Am. J. Physiol.</u> , 259:E-457-E461 (1983)	
	AI10	Young <i>et al.</i> , "Amylin Activated Glycogen Phosphorylase in the Isolated Soleus Muscle of the Rat", <u>FEBS Letts.</u> , 281(1,2):149-151 (1991)	
	AJ10	Young <i>et al.</i> , "Amylin and Insulin in Rat Soleus Muscle: Dose Responses for Cosecreted Noncompetitive Antagonists", <u>Am. J. Physiology</u> , 263(2):E274-E281 (1992)	
	AK10	Young <i>et al.</i> , " ⁸⁻³⁷ h-CGRP, an Amylin Receptor Antagonist, Enhances the Insulin Response and Perturbs the Glucose Response to Infused Arginine in Anesthetized Rats", <u>Mol. Cell. Endocrinol.</u> , 84:R1-R5 (1992)	
	AL10	Zhu <i>et al.</i> , "Amylin Increases Cyclic AMP Formation in L6 Myocytes Through Calcitonin Gene-related Peptide Receptors", <u>Biochem. Biophys. Res. Commun.</u> , 177(2):771-776 (1991)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. * Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA11	Zierath <i>et al.</i> , "Human Islet Amyloid Polypeptide at Pharmacological Levels Inhibits Insulin and Phorbol Ester-Stimulated Glucose Transport in <i>In Vitro</i> Incubated Human Muscle Strips", <u>Diabetologia</u> , 35:26-31 (1992)	
	AB11	Zitomer <i>et al.</i> , "Gastric Neuropathy in Diabetes Mellitus: Clinical and Radiologic Observations", <u>Metabolism</u> , 17:199-201 (1968)	
	AC11		
	AD11		
	AE11		
	AF11		
	AG11		
	AH11		
	AI11		
	AJ11		
	AK11		
	AL11		
EXAMINER			DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.</p>			